Business
Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update
Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 Pemvidutide granted Fast Track designation for the treatment of
About this update from Altimmune, Inc.
[{"type":"text","content":"Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 Pemvidutide granted Fast Track designation for the treatment of non-alcoholic steatohepatitis (NASH) Top-line results from the Phase 2 trial of HepTcell™ in chronic hepatitis B (CHB) expected Q1 2024 Webcast to be held today, November 7, 2023, at 8:30 am EST GAITHERSBURG, Md., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended September 30, 2023, and provided a business update. “The next few months will be important as we receive the data from our 48-week MOMENTUM trial of pemvidutide in subjects with obesity as well as the results of our Phase 2 trial of HepTcell in CHB,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “The rapidly expanding obesity market needs differentiated products that address not only excess body weight, but also risk factors for cardiovascular comorbidities, including elevated LDL-cholesterol and excess liver fat. We also were very pleased to receive Fast Track designation for our pemvidutide program in NASH, which demonstrates the unmet need for this critical liver disease. We believe that our liver fat reduction is class-leading and could result in unprecedented reductions of fibrosis and measures of NASH.” Recent Highlights and Anticipated Milestones Pemvidutide Top-line data readout from 48-week MOMENTUM Phase 2 obesity trial expected in Q4 2023 Patient dosing (last subject last dose) was completed in September 2023.Dr. Louis Aronne, Professor of Metabolic Research and Professor of Clinical Medicine, Weil Cornell Medical School, a leading authority in obesity and obesity clinical trials, is serving as the Principal Investigator.391 subjects with obesity or overweight and without diabetes were randomized 1:1:1:1 to 1.2 mg, 1.8 mg, 2.4 mg pemvidutide or placebo administered weekly for 48 weeks in conjunction with diet and exercise.In an interim 24-week data readout in March 2023, subjects receiving pemvidutide achieved robust reductions in body weight, waist circumference, serum lipids and blood pressure without arrhythmias, clinically meaningful heart rate increases or other safety signals.Top-line data readout at 48 weeks will include subject disposition, weight loss, seru...